SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
News Oct 19, 2012
Unlike the fMRI studies currently performed in drug development that require anesthetized, unconscious animals, Ekam Imaging's fMRI translational technology produces detailed maps of a conscious animal's brain activity, a state that much better represents the human condition.
"The rat models created by SAGE Labs have been genetically modified to reflect patient-relevant mutations and exhibit highly relevant, robust phenotypes. The combination of these rats with Ekam's imaging platform presents a transformative opportunity for translational neuroscience programs. Ultimately, these types of studies will lead to better drugs targeting neurodegenerative diseases such as Parkinson's and Alzheimer's diseases," said Edward Weinstein, Ph.D., Director of SAGE Labs.
"Probing the brain functions of a conscious animal, specifically in rats which are prized by the neuroscience community for intelligence and complex social behaviors, produces data that is much more representative of a potential therapy's effects on human processes," said Mark Nedelman, MS, MBA, President and CEO of Ekam Imaging.
Nedelman's company is currently producing a detailed map of neural activity in SAGE Lab's Pink1 gene knockout rat, which SAGE Labs generated for The Michael J. Fox Foundation to model Parkinson's disease. The Pink1 gene knockout rat exhibits delayed-onset motor deficits, a key phenotype of Parkinson's disease in humans.
Sigma and Ekam plan to publicly launch services specific to SAGE Labs' neuroscience rat models in early 2013.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018